Astrocytosis: Cellular Shield of the Brain

Astrocytosis represents one of the central nervous system's most vital yet enigmatic cellular reactions, functioning as both an essential guardian of neural integrity and a potential driver of chronic neuropathology. Whenever brain or spinal tissue encounters trauma, ischemia, infection, or neurodegeneration, astrocytes undergo a profound morphological, biochemical, and functional transformation known as reactive astrocytosis or astrogliosis. Deciphering the intricate signaling pathways that govern this cellular transition has revolutionized modern neuroscience, shifting the scientific paradigm from viewing glia as mere passive connective tissue to recognizing them as dynamic master regulators of central nervous system homeostasis, repair, and immune response.

Astrocytosis

1. Concise Definition

Astrocytosis, frequently termed reactive astrogliosis or reactive astrocytosis, refers to an abnormal increase in the number, size, and metabolic activity of astrocytes—the star-shaped glial cells of the brain and spinal cord—occurring in response to physical trauma, stroke, infection, autoimmune attack, or neurodegenerative pathology. This physiological response is characterized morphologically by cellular hypertrophy, elongation and branching of cytoplasmic processes, and marked transcriptional upregulation of intermediate filament proteins, most notably glial fibrillary acidic protein (GFAP) and vimentin.

Rather than presenting as a uniform, all-or-nothing phenomenon, astrocytosis operates along a highly nuanced, context-dependent spectrum. Depending on the severity, chronicity, and biochemical nature of the underlying neural insult, reactive astrocytes can exert powerful neuroprotective effects—such as maintaining the blood-brain barrier, sequestering toxic metabolites, replenishing energetic substrates, and limiting tissue damage through glial scar formation—or adopt cytotoxic, neuroinflammatory phenotypes that impair axonal regeneration, disrupt synaptic transmission, and accelerate neuronal loss.

2. Etymology & Linguistic Origin

The term astrocytosis is derived from classical linguistic roots in ancient Greek and late scientific Latin. The initial morpheme originates from the Ancient Greek ástron (αἄστρον), meaning "star" or "celestial body," which was selected by nineteenth-century neurohistologists to describe the radiating, starlike cytoplasmic morphology of these specialized neuroglial cells. The combining form kýtos (κýτος) translates literally to "hollow vessel," "container," or modernly "cell."

The suffix -osis (ωσις) denotes a condition, process, state of disease, or abnormal increase in quantity, particularly within medical terminology. Thus, the etymological synthesis of astrocytosis strictly denotes "a state characterized by an increase or proliferation of star-like cells." The related terminology astrogliosis incorporates the Greek root glía (γλíα), meaning "glue," underscoring the classical, historical concept introduced by Rudolf Virchow that glial cells functioned primarily as structural cement holding the neuronal architecture together.

3. Pronunciation & Grammatical Form

Astrocytosis is pronounced phonetically as /æs.troʊ.saɪˈtoʊ.sɪs/ (as-troh-sy-TOH-sis). It operates grammatically as an uncountable noun in English biomedical prose. The plural form, when utilized to describe multiple discrete pathological events or regional occurrences, is written as astrocytoses (/æs.troʊ.saɪˈtoʊ.siːz/).

The adjective derived from this construct is astrocytic (e.g., "astrocytic activation," "astrocytic scar"), while cells exhibiting this reactive phenotype are referred to as reactive astrocytes or gemistocytic astrocytes when markedly swollen with abundant eosinophilic cytoplasm. In clinical and laboratory contexts, the term is frequently used interchangeably with reactive astrogliosis, though purists may distinguish astrocytosis as denoting cell proliferation specifically and astrogliosis as encompassing the entire molecular and structural spectrum of astrocyte remodeling.

4. Detailed Conceptual Explanation

Under non-pathological baseline conditions in the healthy central nervous system (CNS), mature protoplasmic astrocytes in gray matter and fibrous astrocytes in white matter occupy non-overlapping, tiled anatomical domains. Through delicate perivascular end-feet and millions of fine peripheral processes, baseline astrocytes regulate local cerebral blood flow, clear excessive neurotransmitters such as glutamate from the synaptic cleft, buffer extracellular potassium ions, supply metabolic fuel via the astrocyte-neuron lactate shuttle, and modulate synaptic plasticity. They constitute essential partners in the "tripartite synapse," actively listening and responding to chemical communication between pre- and post-synaptic neurons.

When an acute or insidious insult disturbs brain homeostasis, quiescent astrocytes rapidly exit their resting state. The triggering stimuli are diverse, encompassing damage-associated molecular patterns (DAMPs) released from ruptured neurons, pathogen-associated molecular patterns (PAMPs), extravasated blood components like fibrinogen, reactive oxygen species (ROS), and cytokines secreted by resident microglia or infiltrating peripheral immune cells, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). Upon sensing these cues through membrane-bound pattern recognition receptors and cytokine receptors, intracellular signaling cascades are ignited, including the JAK/STAT3 (Janus kinase / signal transducer and activator of transcription 3), NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), and MAPK (mitogen-activated protein kinase) pathways.

Activation of these transcription factors coordinates broad genomic and epigenetic reprogramming. The astrocyte increases synthesis of cytoskeletal intermediate filaments, primarily GFAP, vimentin, and nestin, which reinforces cellular tensile strength and causes substantial hypertrophy of primary and secondary processes. Concurrently, reactive astrocytes alter their secretome, releasing growth factors (such as nerve growth factor, brain-derived neurotrophic factor, and vascular endothelial growth factor), trophic support molecules, matrix metalloproteinases, and chemokines that recruit circulating leukocytes.

A critical paradigm in understanding modern astrocytosis is recognizing that the process is not monolithic. In mild to moderate insults, such as mild concussion or distant metabolic derangements, astrocytes exhibit non-proliferative, reversible astrocytosis where individual cells hypertrophy but remain strictly confined within their individual spatial domains without disrupting local architecture. However, following severe focal trauma, ischemic infarction, or invasive infection, astrocytosis culminates in severe, irreversible remodeling: astrocytes proliferate, lose their domain organization, interweave their extended processes, and deposit dense chondroitin sulfate proteoglycans (CSPGs) to form a permanent physical barrier known as a glial scar.

5. Historical Development

The conceptual framework of astrocytosis developed in tandem with the evolution of neurohistology throughout the nineteenth and twentieth centuries. In 1858, German pathologist Rudolf Virchow first characterized neuroglia as an interstitial substance or "nerve cement" that provided passive mechanical support for neurons. In the decades that followed, Hungarian histologist Mihály Lenhossék coined the term astrocyte in 1893 to describe the distinct starlike cells visualized through improved staining techniques.

The advent of heavy-metal impregnation staining pioneered by Camillo Golgi and refined by Santiago Ramón y Cajal and his disciple Pío del Río-Hortega in the early 1900s allowed researchers to observe reactive changes directly. Cajal documented marked morphological alterations in astrocytes surrounding brain lesions, noting that these cells expanded their processes toward the injury site in what he termed an "active proliferative reaction." For much of the twentieth century, however, neuropathologists regarded reactive astrocytosis primarily as an inert, end-stage scar tissue—analogous to fibrotic scarring in peripheral organs—whose sole biological consequence was the mechanical blockage of axonal regrowth.

This reductionist view underwent a profound transformation in the 1970s and 1980s with the discovery of intermediate filament proteins, particularly Eng and colleagues' identification of GFAP as a specific marker for reactive astrocytes. The development of transgenic mouse models in the late 1990s and early 2000s, spearheaded by researchers such as Michael Sofroniew, definitively established that preventing or ablating reactive astrocytosis leads to massive exacerbation of neuronal death, failure to repair the blood-brain barrier, and widespread leukocyte invasion. By the 2010s, high-throughput single-cell RNA sequencing further uncovered staggering heterogeneity among reactive astrocyte subsets, dismantling simplistic binary views and initiating the contemporary era of molecularly categorized astrocytic states.

6. Theoretical Foundations

The theoretical architecture framing modern astrocytosis rests upon principles of cellular plasticity, systems neurobiology, and inflammatory regulation. At its core, astrocytosis is understood through the Evolutionary Adaptation Framework of Neural Repair. Because the mammalian central nervous system possesses negligible intrinsic capacity for spontaneous axonal regeneration across extensive parenchymal gaps, evolutionary selection favored a rapid, robust tissue containment strategy over permissive regeneration. Astrocytosis evolved as a damage-control mechanism: the primary evolutionary imperative is to seal off infectious agents, isolate necrotic debris, reconstitute the physiological blood-brain barrier, and prevent the catastrophic spread of cytotoxic cytokines into undamaged neural circuits.

A second foundational theory involves the Multi-State Reactive Polarization Continuum. In 2017, pioneering work proposed a binary classification modeled after macrophage polarization, designating reactive astrocytes as either "A1" (classically activated, neurotoxic, induced by microglial-derived IL-1α, TNF-α, and C1q) or "A2" (alternatively activated, neuroprotective, induced by ischemia). However, international consensus statements published in 2021 by leading neurobiologists (Escartin et al.) revised this model, establishing that astrocytosis cannot be accurately captured by static binary labels. Instead, reactive astrocytes populate a multidimensional transcriptional spectrum determined dynamically by the spatial distance from the lesion epicenter, the specific cocktail of initiating molecular ligands, and local metabolic constraints.

A third theoretical pillar is the Glial Syncytium Disruption Hypothesis. Astrocytes are physiologically coupled to one another via gap junctions composed predominantly of connexin-43 (Cx43) and connexin-30 (Cx30), forming an extensive syncytium capable of spatial potassium buffering and long-range calcium signaling. In pathological astrocytosis, uncoupling or pathological alteration of gap junctional communication disrupts homeostatic buffering, shifting the astrocyte from a cooperative network participant into an autonomous effector of localized inflammation and tissue remodeling.

7. Key Components, Types & Dimensions

Astrocytosis manifests across distinct morphological, molecular, and spatial dimensions depending upon the pathological context:

• Mild Non-Proliferative Astrocytosis: Characterized by mild hypertrophy of cell soma and primary processes with upregulation of GFAP expression. The astrocytes retain their individual spatial domains, and there is no cellular proliferation or significant tissue restructuring. This form is common in remote trauma, mild systemic metabolic disturbances, or early stages of neurodegeneration, and it is largely reversible once the inciting stressor resolves.
• Moderate Astrocytosis: Displays prominent cellular hypertrophy, extended elongation of branching processes, and marked elevation of GFAP and vimentin. Astrocytic domains begin to overlap slightly, accompanied by modulation of neurotrophic support and localized cytokine secretion, though extensive scarring does not occur.
• Severe Scar-Forming Astrocytosis (Glial Scarring): Triggered by severe physical disruption, deep penetrating trauma, brain abscesses, or large ischemic strokes. Astrocytes undergo cell cycle reentry and proliferation, permanently abandon domain organization, extend interwoven dense cellular processes, and deposit an extracellular matrix packed with inhibitory chondroitin sulfate proteoglycans (CSPGs like neurocan, aggrecan, and versican) that form a permanent physical and biochemical seal around the lesion core.
• Isomorphic vs. Anisomorphic Astrocytosis: Classical neuropathological designations distinguishing whether the original cytoarchitectural framework of the tissue is preserved (isomorphic, with parallel glial fibers seen in demyelinating plaques) or completely disintegrated and replaced by haphazard, dense astrocytic meshwork (anisomorphic, typical of infarcts and trauma).
• Gemistocytic Astrocytosis: A histopathological subtype wherein reactive astrocytes develop markedly distended, rounded, eosinophilic cytoplasm with eccentric nuclei and coarse, plump processes, typically observed in acute cerebral infarctions, active demyelinating lesions, and certain astrocytic neoplasms.

8. Examples & Illustrative Cases

To understand the dynamic behavior of astrocytosis across different clinical contexts, consider two illustrative scenarios reflecting acute focal damage versus chronic systemic neurodegeneration:

Case Illustration 1: Acute Middle Cerebral Artery Ischemia
A 68-year-old patient suffers an embolic occlusion of the middle cerebral artery, resulting in acute ischemic stroke. In the central ischemic core, severe energy deprivation and rapid ATP depletion cause irreversible necrosis of both neurons and astrocytes. However, in the surrounding penumbra—where collateral circulation provides marginal perfusion—astrocytes detect hypoxia-inducible factor 1-alpha (HIF-1α) activation and extracellular ATP spilled from dead cells. Over the subsequent 72 hours, these penumbral astrocytes swell, activate the STAT3 pathway, and exhibit profound astrocytosis. They clear excessive extracellular glutamate through remaining EAAT2 (excitatory amino acid transporter 2) transporters, mitigating excitotoxic neuronal death, and form a tight glial scar bordering the infarct by day 14. This reactive border successfully contains neurotoxic debris and prevents secondary inflammatory spread, though the dense accumulation of CSPGs simultaneously inhibits long-term axonal sprouting across the infarct boundary.

Case Illustration 2: Amyotrophic Lateral Sclerosis (ALS)
A 55-year-old patient presents with progressive muscle weakness and fasciculations, subsequently diagnosed with ALS involving mutations in the superoxide dismutase 1 (SOD1) gene. Unlike the acute localized scar seen in ischemic stroke, astrocytosis in this patient is chronic, diffuse, and progressive throughout the motor cortex and anterior horns of the spinal cord. Reactive astrocytes in these regions selectively downregulate EAAT2, leading to prolonged synaptic glutamate dwell time and sustained excitotoxic stress on lower motor neurons. Concurrently, these reactive astrocytes secrete pro-inflammatory cytokines, reactive nitrogen species, and neurotoxic factors that accelerate motor neuron apoptosis. In this chronic context, astrocytosis ceases to be protective, becoming a critical secondary driver of disease acceleration.

9. Measurement & Assessment

The detection and quantification of astrocytosis span post-mortem neuropathology, preclinical molecular biological assays, and modern in vivo neuroimaging and fluid biomarker technology:

• Immunohistochemistry and Immunofluorescence: In tissue biopsy or post-mortem histological sections, astrocytosis is verified using antibodies targeting intermediate filaments, primarily GFAP, vimentin, and nestin. Astrocytic hypertrophy and process density are quantified using digital image thresholding and Sholl analysis, which calculates the branching complexity and spatial span of individual cells. Additional markers such as S100B, ALDH1L1 (aldehyde dehydrogenase 1 family member L1), and connexin-43 are used to identify total astrocyte populations regardless of activation state.
• Transcriptomic Profiling: Preclinical and translational studies evaluate astrocytic activation states via bulk, single-cell, or spatial RNA sequencing. Upregulation of gene panels including Gfap, Serpina3n, Lcn2 (lipocalin-2), and complement cascade components (such as C3) provides molecular signatures of the underlying reactive state.
• Positron Emission Tomography (PET) Imaging: In vivo assessment in living human patients is achieved utilizing radiotracers designed to bind specifically to astrocytic enzyme targets. The foremost radiotracer is [¹¹C]-deuterium-L-deprenyl ([¹¹C]-DED), which targets monoamine oxidase B (MAO-B), an enzyme robustly overexpressed in reactive astrocytes during neurodegenerative processes such as early Alzheimer's disease. Radioligands targeting the imidazoline-2 binding site (I₂BS) also serve as active diagnostic probes.
• Fluid Biomarkers (CSF and Blood): GFAP has transitioned into clinical diagnostics as a primary biofluid biomarker. Following acute traumatic brain injury (TBI) or during active neurodegenerative disease, cellular disruption and active exosome secretion release GFAP into the cerebrospinal fluid and bloodstream. High-sensitivity single-molecule array (Simoa) platforms detect picogram levels of plasma GFAP, serving as an FDA-cleared diagnostic marker to determine the need for CT scans after acute head trauma and tracking disease activity in multiple sclerosis and Alzheimer's disease.

10. Applications & Practical Significance

The study of astrocytosis carries profound translational significance across several medical disciplines, particularly neurology, neurosurgery, and drug discovery:

In neurotrauma and critical care, measuring blood GFAP levels allows clinicians to rapidly triage patients presenting with mild traumatic brain injury, distinguishing individuals who harbor occult intracranial hemorrhages from those who can be safely discharged without expensive ionizing imaging. In spinal cord injury, modulating the timing of astrocytic scar formation represents an active therapeutic frontier: preserving early astrocytic scar formation is essential to restrict lesion spread and prevent massive systemic leukocyte infiltration, whereas dissolving late-stage inhibitory extracellular matrix components (such as CSPG degradation via enzymatic chondroitinase ABC delivery) promotes functional axonal regeneration and motor recovery.

In neuro-oncology, astrocytosis represents a critical diagnostic challenge. Distinguishing exuberant, reactive, gemistocytic astrocytosis from low-grade infiltrating diffuse astrocytomas requires sophisticated molecular testing. Reactive astrocytes retain intact TP53 wild-type genetics, lack IDH1/2 (isocitrate dehydrogenase) mutations, and preserve nuclear ATRX expression, whereas diffuse astrocytic neoplasms demonstrate diagnostic clonal somatic mutations. Understanding tumor-associated astrocytosis also reveals how glioblastomas co-opt surrounding non-malignant reactive astrocytes into immunosuppressive "tumor niches" that foster invasiveness and therapeutic resistance.

11. Research & Empirical Evidence

Decades of empirical investigation have delineated the molecular cascades that drive astrocytosis. Groundbreaking work by Michael Sofroniew and colleagues utilizing transgenic herpes simplex virus-thymidine kinase (HSV-TK) driven by the GFAP promoter allowed the selective, inducible pharmacological ablation of proliferating reactive astrocytes in rodent models of spinal cord injury and cortical trauma. In these studies, ablated animals exhibited massive failure of blood-brain barrier repair, unbounded infiltration of CD45+ leukocytes, extensive tissue necrosis, and significantly worse motor outcomes compared to wild-type controls, confirming the indispensable neuroprotective role of early astrocytic scar formation.

In parallel, work conducted by Shane Liddelow, Ben Barres, and colleagues in 2017 characterized the molecular induction of toxic reactive astrocytes. They demonstrated that activated microglia, upon encountering bacterial lipopolysaccharide (LPS), secrete a specific triumvirate of cytokines—interleukin-1 alpha (IL-1α), tumor necrosis factor (TNF), and complement component 1q (C1q)—which in turn induces a neurotoxic astrocytic phenotype. These induced reactive astrocytes lost their physiological abilities to promote neuronal survival, form new synapses, and phagocytose myelin debris, while aggressively secreting a neurotoxic factor that rapidly induced apoptosis in mature CNS neurons and oligodendrocytes.

Contemporary empirical studies have focused on resolving this reaction at the single-cell resolution. Multi-omic single-nucleus transcriptomic atlases of human post-mortem brains afflicted by Alzheimer's, Parkinson's, and Huntington's diseases have identified distinct sub-clusters of reactive astrocytes associated with disease severity. These studies show that chronic neuroinflammation dampens essential homeostatic genes (such as SLC1A2, encoding EAAT2, and GLUL, encoding glutamine synthetase) while activating lipid metabolism and interferon-response pathways, directly correlating with cognitive decline.

12. Cultural & Cross-Cultural Considerations

Because astrocytosis describes a fundamental cell-biological and histopathological process common to all human nervous systems, its fundamental cellular mechanics do not vary by human culture or race. However, significant variations emerge regarding how astrocytic pathologies are assessed, prioritized, and diagnosed in health systems globally.

High-income healthcare systems increasingly incorporate ultra-sensitive blood-based biomarkers (such as plasma GFAP via Simoa) and specialized neuroimaging (PET imaging targeting MAO-B) into standard neurodegenerative and neurotrauma care pathways. Conversely, resource-limited clinical environments often lack access to automated chemiluminescent digital immunoassays and immunohistochemical staining suites, relying heavily on conventional clinical assessments and late-stage non-contrast CT imaging. Furthermore, the prevalence of underlying environmental triggers that induce chronic reactive astrocytosis—such as endemic central nervous system infectious diseases (cerebral malaria, neurocysticercosis, tuberculosis, and HIV-associated neurocognitive disorders) or untreated repetitive head impacts—varies widely across geopolitical regions, affecting the baseline state of glial activation across populations.

13. Criticisms, Debates & Limitations

Despite significant progress, the study of astrocytosis remains immersed in vigorous scientific controversy. A major debate centers around the oversimplified binary classification of reactive astrocytes. Following the introduction of the "A1" (neurotoxic) versus "A2" (neuroprotective) nomenclature, extensive literature adopted this framework uncritically, assuming that astrocytes could be neatly divided into two distinct, static categories. A landmark 2021 consensus critique signed by over 40 prominent glial researchers emphasized that this dichotomy is deeply flawed: reactive astrocytes in living tissue display complex, overlapping, and fluid phenotypes that reflect multidimensional cellular states rather than rigid cell types. Critics argue that relying on binary markers obscures the rich, nuanced, and diverse roles astrocytes play in varying pathological microenvironments.

A second long-standing dispute concerns the role of the glial scar in axonal regeneration. For over a century, the astrocytic scar was regarded by neuroscientists as the primary impediment preventing axonal regrowth after spinal cord injury, motivating decades of experimental therapies aimed at abolishing or dissolving scar tissue. However, Anderson, Sofroniew, and colleagues challenged this dogma by demonstrating that genetic prevention of astrocytic scar formation failed to promote spontaneous axonal regrowth through spinal lesions, and in fact exacerbated tissue degeneration. This finding prompted fierce debate within the neurotrauma community regarding whether future therapeutic strategies should seek to preserve, dissolve, or molecularly reprogram the reactive glial interface.

14. Related Terms & Distinctions

Astrocytosis is frequently discussed alongside several closely related neurobiological concepts, requiring precise differentiation:

• Astrocytosis vs. Microgliosis: While astrocytosis involves the activation, hypertrophy, and potential proliferation of neuroectoderm-derived astrocytes, microgliosis (reactive microgliosis) refers to the activation, morphological retraction, and proliferation of microglia—the resident macrophage-like immune cells of the CNS, which originate from yolk-sac mesoderm. Microglia typically respond first to acute insults, releasing cytokines that subsequently drive astrocytosis.
• Astrocytosis vs. Gliosis: Gliosis is an overarching umbrella term describing the non-specific reactive proliferation and hypertrophy of any glial cell population within the CNS, including astrocytes, microglia, oligodendrocytes, and oligodendrocyte precursor cells (NG2 glia). Astrocytosis is specifically restricted to the astrocytic lineage.
• Astrocytosis vs. Astrocytoma: Astrocytosis is a non-neoplastic, reactive, physiological response to injury or disease, wherein cellular proliferation remains under strict genetic and homeostatic control and typically regresses or stabilizes. In contrast, an astrocytoma is a true neoplastic, clonal, uncontrolled proliferation of astrocytic lineage cells driven by oncogenic driver mutations (such as IDH, TP53, or EGFR alterations), possessing autonomous growth capacity and invasive potential.
• Glial Scar vs. Fibrotic Scar: The mature astrocytic glial scar is formed by overlapping, densely packed astrocyte processes and specialized proteoglycans that seal the CNS parenchyma. In contrast, a fibrotic scar (often located at the lesion core of penetrating wounds) is formed by collagen-depositing stromal fibroblasts, pericytes, and meningeal cells that infiltrate through disrupted blood vessels or meninges.

15. Summary & Key Takeaways

Astrocytosis is the central nervous system's universal, highly coordinated response to tissue disturbance. Rather than acting as a static scar or passive bystander, the reactive astrocyte serves as a primary conductor of neural repair, neuroinflammation, and metabolic defense. Key insights include:

• Astrocytosis spans a broad continuum ranging from mild, reversible cellular hypertrophy with preserved domain structure to severe, irreversible glial scarring marked by cell proliferation, overlapping domains, and physical barriers.
• Intermediate filaments, specifically GFAP and vimentin, serve as universal hallmarks of this transition, with plasma GFAP now established as a pivotal clinical biomarker for traumatic brain injury and neurodegeneration.
• Astrocytes are intrinsically dual-faceted: their reactive transformation preserves tissue architecture, re-establishes the blood-brain barrier, and confines inflammation, yet maladaptive or chronic reactive states can release toxic factors, exacerbate excitotoxicity, and prevent axonal regeneration.
• Contemporary consensus rejects simplistic binary models (such as static "A1/A2" categorizations), recognizing that astrocytic phenotypes are multidimensional and dictated by local microenvironmental cues.

Ultimately, astrocytosis exemplifies the complex evolutionary compromises underpinning mammalian brain architecture: a cellular defense system engineered for immediate containment and short-term survival that, under chronic or excessive strain, can become a contributor to persistent neuropathology. Mastering the ability to selectively amplify its neuroprotective dimensions while dampening its destructive neuroinflammatory pathways represents one of the most promising frontiers in modern neurology.

References

• Anderson, M. A., Burda, J. E., Ren, Y., Ao, Y., O'Shea, T. M., Kawaguchi, R., Coppola, G., Khakh, B. S., Deming, P. B., & Sofroniew, M. V. (2016). Astrocyte scar formation aids central nervous system axon regeneration. Nature, 532(7598), 195–200. https://doi.org/10.1038/nature17623
• Burda, J. E., & Sofroniew, M. V. (2014). Reactive astrogliosis and the multicellular response to CNS damage and disease. Neuron, 81(2), 229–248. https://doi.org/10.1016/j.neuron.2013.12.034
• Escartin, C., Galea, E., Lakatos, A., O'Callaghan, J. P., Petzold, G. C., Serrano-Pozo, A., Steinhäuser, C., Volterra, A., Carmignoto, G., Pekny, M., Verkhratsky, A., & Sofroniew, M. V. (2021). Reactive astrocyte nomenclature, definitions, and future directions. Nature Neuroscience, 24(3), 312–325. https://doi.org/10.1038/s41593-020-00783-4
• Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W. S., Peterson, T. C., Wilton, D. K., Frouin, A., Napier, B. A., Panicker, N., Kumar, M., Buckwalter, M. S., Rowitch, D. H., Dawson, V. L., Dawson, T. M., … Barres, B. A. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature, 541(7638), 481–487. https://doi.org/10.1038/nature21029
• Pekny, M., & Pekna, M. (2014). Astrocyte reactivity and reactive astrogliosis: Costs and benefits. Physiological Reviews, 94(4), 1077–1098. https://doi.org/10.1152/physrev.00041.2013
• Sofroniew, M. V. (2009). Molecular dissection of reactive astrogliosis and glial scar formation. Trends in Neurosciences, 32(12), 638–647. https://doi.org/10.1016/j.tins.2009.08.002
• Verkhratsky, A., & Nedergaard, M. (2018). Physiology of astroglia. Physiological Reviews, 98(1), 239–389. https://doi.org/10.1152/physrev.00042.2016